Global

News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

14 February 2017 FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition

Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s clinical efficacy supplement to its Biologics License Application (BLA) for Privigen® [Immune Globulin Intravenous (Human), 10% Liquid], its intravenous immunoglobulin (IVIg).

> Read More
09 January 2017 AFSTYLA®, for Haemophilia A, Receives European Commission Approval

Global biotherapeutics leader CSL Behring announced today that the European Commission has granted marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for children and adults with haemophilia A.

> Read More
05 January 2017 Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors

Momenta and CSL have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins.

> Read More
22 December 2016 CSL CEO Says Holistic Approach to Business is Essential to Corporate Sustainability, the Company's Value Chain and Patients

CSL released its 2015-2016 Corporate Responsibility Report, which details company performance in key social, environmental and economic priority areas.

> Read More
14 December 2016 Health Canada Approves CSL Behring’s AFSTYLA for the Treatment of Hemophilia A

Health Canada has approved AFSTYLA [Antihemophilic Factor VIII (Recombinant), SingleChain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.

> Read More
Page 1 of 8 Next | Last

Share
LinkedIn Twitter Facebook Google+